Tech Sharing_Borryen Pharmaceutical | Precision drug analysis

Bryheng Peptide Analysis Platform! LC-MS/MS technology precisely powers GLP-1 drug development, driving new breakthroughs in metabolic therapies.

In the fields of diabetes and obesity treatment, GLP-1 receptor agonists have undoubtedly emerged as a shining star. Drugs such as semaglutide, liraglutide, exenatide, and tirzepatide are reshaping the lives of hundreds of millions of patients worldwide, thanks to their remarkable blood sugar-lowering and weight-loss effects.

2025-09-01

Bryheng Peptide Analysis Platform! LC-MS/MS technology precisely powers GLP-1 drug development, driving new breakthroughs in metabolic therapies.

Breaking Through Challenges in Insulin Compound Detection: The Success Story of BoreiHeng Pharmaceutical Technology

In the field of diabetes drug development and treatment monitoring, accurately measuring the blood concentrations of insulin and its analogs—such as human insulin, aspart insulin, glargine insulin, and degludec insulin—presents a central challenge. These compounds, characterized by their large molecular weights, significant endogenous interference, and extremely low exposure levels, place nearly exacting demands on analytical methods. Thanks to its deep-rooted technological expertise, Wuhan Brightrun Pharmaceutical Technology Co., Ltd. has successfully overcome these industry hurdles.

2025-07-23

Breaking Through Challenges in Insulin Compound Detection: The Success Story of BoreiHeng Pharmaceutical Technology

Breakthrough! Wuhan Buruiheng Pharmaceutical Technology Co., Ltd. Launches a New Era in Bio-Detection with Estrogen/Estrone Testing

In clinical diagnostics and medical research, precise measurement of estradiol and estrone levels is critically important. Estradiol plays a key role in female reproduction and male metabolism, while estrone is involved in endocrine regulation. Abnormal fluctuations in the levels of these two hormones have been linked to various diseases. However, detecting them poses significant challenges: as they are naturally occurring endogenous substances, conventional methods cannot be used to create reliable standard curves. Additionally, the commonly employed surrogate matrix approach is often cumbersome and complex to implement. Moreover, steroids in biological matrices exist in both bound and unbound forms, and without proper reference standards, enzymatic hydrolysis-based quantitative analysis requires carefully optimized conditions. On top of this, current detection methods struggle to achieve the ultra-low quantification limits required—often down to the picogram level—while also demanding relatively large sample volumes, which can limit the analysis of precious or limited samples. Fortunately, our company has just announced exciting progress in the field of bioanalysis, offering promising solutions that could overcome these longstanding challenges.

2025-05-15

Breakthrough! Wuhan Buruiheng Pharmaceutical Technology Co., Ltd. Launches a New Era in Bio-Detection with Estrogen/Estrone Testing

Beriheng Project Experience and Analysis Methodology Catalog (as of June 2023)

As of June 2023, Berryheng has been approved for 33 projects, verified 20 projects, and exempted from verification in 20 projects. For details, please see the chart below:

2023-07-18

Beriheng Project Experience and Analysis Methodology Catalog (as of June 2023)

Good News | Berriheng Helps Yueyang Xinhua Dafu's Bisoprolol Fumarate Tablets Pass Generic Drug Consistency Evaluation!

In May 2020, Yueyang Xinhua Da Pharmaceutical Co., Ltd. (hereinafter referred to as "Yueyang Xinhua Da Pharmaceutical") received the "Drug Supplementary Application Approval" for Bisoprolol Fumarate Tablets (5mg per tablet, Acceptance No.: CYHB1950120), issued and approved by the National Medical Products Administration. The drug has successfully passed the evaluation of quality and therapeutic equivalence for generic drugs.

2020-06-30

Good News | Berriheng Helps Yueyang Xinhua Dafu's Bisoprolol Fumarate Tablets Pass Generic Drug Consistency Evaluation!

< 1 > proceed page

Wuhan Brightrun Pharmaceutical Technology Co., Ltd.

Mobile: 8619913181561 (Ms. Wang)

Email: bd@whbrh.cn

Address: Building B4, Optics Valley Bio-city, 666 Gaoxin Avenue, Hongshan District, Wuhan City

WeChat

WhatsApp：8619913181561

E-mail：bd@whbrh.cn

Tel：8619913181561

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

武汉伯瑞恒医药科技有限公司

Blog